A Novel Derivative of Doxorubicin, AD198, Inhibits Canine Transitional Cell Carcinoma and Osteosarcoma Cells In Vitro
September 2015
in “
Drug Design Development and Therapy
”
TLDR AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
The study evaluated AD198, a novel derivative of doxorubicin, for its effects on canine transitional cell carcinoma (K9TCC) and osteosarcoma (K9OSA) cell lines in vitro. AD198 effectively inhibited cell growth and induced apoptosis through PKC-δ and p38 signaling pathways, showing greater potency and reduced cardiotoxicity compared to doxorubicin. The research involved three K9TCC and three K9OSA primary cancer cell lines, demonstrating AD198's potential as a therapeutic option with fewer adverse effects. These findings suggested that AD198 could be a promising alternative chemotherapy drug for treating these canine cancers, with implications for human cancer therapies.
